Regional disease characteristics and comorbidities of patients with schizophrenia in the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): Findings from an international large simple trial

John M. Kane, Wolfgang Fleischhacker, Francesca Kolitsopoulos, Onur N. Karayal, Jamie Geier, Cynthia Siu, Robert Reynolds, Gerald Faich, Brian L. Strom

Data Power (DP), Inc., Ringoes, USA.
Department of Biological Psychiatry, Medical University Innsbruck, Innsbruck, Austria.
Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Center for Pharmacoepidemiology Research and Training, University of Pennsylvania School of Medicine, Philadelphia, USA.
Department of Epidemiology, United BioSource Corporation, Blue Bell, USA.
Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, USA.
Pfizer Inc., New York, USA.

DOI: 10.4236/ojpsych.2012.224059                

Abstract

Background: Using baseline data from the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC), we assessed disease characteristics and prevalence of select comorbidities among subjects with schizophrenia in different clinical settings across 18 countries. ZODIAC was a randomized, open-label, one-year, large simple trial (LST) that enrolled 18,239 individuals with schizophrenia. Methods: Subjects were randomized to open-label treatment with ziprasidone (n = 9120) or olanzapine (n = 9119) in naturalistic (usual care) settings and followed for one year. Study sites (n = 749) applied minimal selection criteria in an attempt to make the study population as representative as possible of those receiving treatment in “real world” circumstances across the countries. Results: Mean patient age was 41 years, 55% were male, 34% were markedly ill or presented with more severe disease, and 66% of subjects had one or more select comorbid conditions [i.e. heart attack, stroke, hypertension, CAD/angina, high cholesterol/triglycerides, diabetes, or overweight (BMI ≥ 25)] at baseline. History of suicide attempt was greatest in the US (38%), compared with Sweden (34%), Brazil/South America (26%), Asia (23%), and Eastern Europe (20%). Overweight or obesity was the most prevalent comorbid risk factor, representing 60% of enrolled subjects, 70% of US subjects compared with 30% in Asia and 52% - 64% in the other regions studied. High cholesterol/triglycerides levels were found in 23% of US subjects compared with a relatively low prevalence in other countries (3% - 11%). History of cardiovascular or diabetes-related comorbidities was found in 31% of subjects. Current smoking (46.5%) and past smoking (11.8%) were common with men dominating the proportion of current smokers: US (61%); Asia (60%); Sweden (50%); Eastern Europe (49%); and Latin America (44%). Conclusions: Our findings indicate substantial baseline variations across countries in demographics, comorbid conditions, and psychiatric disease history. These data provide an international epidemiologic picture of schizophrenia and may help guide future research and treatment initiatives.

Keywords

Large Simple Trial; Schizophrenia; ZODIAC; Comorbidities

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Karagianis, J., Novick, D., Pecenak, J., et al. (2009) Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): Baseline characteristics of pan-regional observational data from more than 17,000 patients. International Journal of Clinical Practice, 63, 1578-1588. doi:10.1111/j.1742-1241.2009.02191.x
[2]	Peto, R., Collins, R., Gray, R. (1995) Large-scale randomized trials and overviews of trials. Journal of Clinical Epidemiology, 48, 23-40. doi:10.1016/0895-4356(94)00150-O
[3]	Peto, R., Baigent, C. (1998) Trials: The next 50 years: Large scale randomized evidence of moderate benefits. British Medical Journal, 317, 1170-1171. doi:10.1136/bmj.317.7167.1170
[4]	Stroup, T.S. (2011) What can large simple trials do for psychiatry? America Journal of Psychiatry, 168, 117-119. doi:10.1176/appi.ajp.2010.10111652
[5]	Thornley, B., Adams, C. (1998) Content and quality of 2000 controlled trials in schizophrenia over 50 years. British Medical Journal, 317, 1181-1184. doi:10.1136/bmj.317.7167.1181
[6]	Saxena, S., Paraje, G., Sharen, P., et al. (2006) The 10/90 divide in mental health research trends over a 10-year period. The British Journal of Psychiatry, 188, 81-82. doi:10.1192/bjp.bp.105.011221
[7]	Saxana, S., Thornicroft, G., Krapp, M., Whiteford, H. (2007) Resources for mental health: Scarcity, inequality and inefficiency. Lancet, 370, 878-889. doi:10.1016/S0140-6736(07)61239-2
[8]	Patel, V., Prince, M. (2010) Global mental health: A new global health field comes of age. Journal of the American Medical Association, 303, 1976-1977. doi:10.1001/jama.2010.616
[9]	The World Health Organization (WHO) (2010) Movement for Global Mental Health and mhGAP (the mental health Global Action Program). Http://www.globalmentalhealth.org
[10]	Strom, B.L., Eng, S.M., Faich, G., et al. (2011) Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 subjects with schizophrenia: The Ziprasidone Observational study of Cardiac Outcome (ZODIAC). American Journal of Psychiatry, 168, 193-201. doi:10.1176/appi.ajp.2010.08040484
[11]	Strom, B.L., Faich, G.A., Reynolds, R.F., et al. (2008) The Ziprasidone Observational Study of Cardiac Out- comes (ZODIAC): Designs and baseline subject characteristics. Journal of Clinical Psychiatry, 69, 114-121.
[12]	Dossenbach, M., Erol, A., el Mahfoud-Kessaci, M. et al. (2004) Effectiveness of antipsychotic treatments for schizophrenia: Interim 6-month analysis from a prospective, observational study (IC-SOHO) study comparing olanzapine, quetiapine, risperidone and haloperidol. Journal of Clinical Psychiatry, 65, 312-321. doi:10.4088/JCP.v65n0305
[13]	Haro, J.M., Edgell, E.T., Jones, P.B., et al. (2003) The European Schizophrenia Outpatient Health Outcomes (SOHO) study: Rationale, methods and recruitment. Acta Psychiatrica Scandinavica, 107, 222-232. doi:10.1034/j.1600-0447.2003.00064.x
[14]	De Hert, M., et al. (2010) The METEOR study of diabetes and other metabolic disorders in patients with schizophrenia treated with antipsychotic drugs. I. Methodology. International Journal of Methods in Psychiatric Research, 19, 195-210. doi:10.1002/mpr.322
[15]	Thomas, S.H.L., Drici, M.D., Hall, G.C., et al. (2010) Safety of sertindole versus risperidone in schizophrenia: Principal results of the sertindole cohort prospective study (SCoP). Acta Psychiatrica Scandinavica, 122. 345-355. doi:10.1111/j.1600-0447.2010.01563.x
[16]	Furedi, J., Mohr, P., Swingler, D., et al. (2006) Psychiatry in selected countries of Central and Eastern Europe: An overview of the current situation. Acta Psychiatrica Scandinavica, 114, 223-231. doi:10.1111/j.1600-0447.2006.00804.x
[17]	Kosnar, K. (2003) Mentally ill patients in Central Europe being kept in padlocked, caged beds. British Medical Journal, 327, 1249. doi:10.1136/bmj.327.7426.1249-c
[18]	Polubinskaya, S.V. (2000) Reform in psychiatry in post- Soviet countries. Acta Psychiatrica Scandinavica, 101, 106-108. doi:10.1111/j.0902-4441.2000.007s020[dash]24.x
[19]	Rybakowski, J.K. (2004) Academic psychiatry in Poland: Adjustment to rapid changes. Molecular Psychiatry, 9, 813-815. doi:10.1038/sj.mp.4001569
[20]	Tomov, T. (2001) Mental health reforms in Eastern Europe. Acta Psychiatrica Scandinavica, 104, 21-26. doi:10.1034/j.1600-0447.2001.1040s2021.x
[21]	Brown, S., Birtwistle, J., Roe, L. et al. (1999) The unhealthy lifestyle of people with schizophrenia. Psychological Medicine, 29, 697-701. doi:10.1017/S0033291798008186
[22]	Hennekens, C.H., Hennekens, A.R., Hollar, D., Casey, D.H. (2005) Schizophrenia and increased risks of cardiovascular disease. American Heart Journal, 150, 1115-1121. doi:10.1016/j.ahj.2005.02.007
[23]	Strassnig, M., Brar, J.S., Ganguli, R. (2003) Nutritional assessment of patients with schizophrenia: A preliminary study. Schizophrenia Bulletin, 29, 393-397. doi:10.1093/oxfordjournals.schbul.a007013
[24]	Auquier, P., Lancon, C., Rouillon, F., Lader, M. (2007) Mortality in schizophrenia. Pharmacoepidemiol Drug Safety, 16, 1308-1312. doi:10.1002/pds.1496
[25]	Osby, U., Correia, N., Brandt, L. et al. (2000) Mortality and causes of death in schizophrenia in Stockholm County, Sweden. Schizophrenia Research, 45, 21-28. doi:10.1016/S0920-9964(99)00191-7
[26]	Saha, S., Chant, D., McGrath, J. (2007) A systematic review of mortality in schizophrenia: is the differential mortality gap worsening? Archives of General Psychiatry, 64, 1123-1131. doi:10.1001/archpsyc.64.10.1123
[27]	The World Health Organization (WHO) (2009) Global health risks: Mortality and burden of disease attributable to selected major risks. WHO Press, Geneva. http://www.who.int/healthinfo/global-burden-disease/GlobalHealthRisks/report/full.pdf
[28]	McEvoy, J.P., Meyer, J.M., Goff, D.C., et al. (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research, 80, 19-32. doi:10.1016/j.schres.2005.07.014
[29]	Newcomer, J.W. (2007) Metabolic syndrome and mental illness. American Journal of Managed Care, 13, S170-S177.
[30]	American Diabetes Association (ADA), American Psychiatric Association, American Association of Clinical Endocrinologists and The North American Association for the Study of Obesity (2004) Consensus development on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27, 51-59.
[31]	Lieberman, J.A., Stroup, T.S., McEvoy, J.P., et al. (for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigators) (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine, 353, 1209-1223. doi:10.1056/NEJMoa051688
[32]	Newcomer, J.W. (2005) Second-generation (atypical) antipsychotics and metabolic side-effects: A comprehensive literature review. CNS Drugs, 19, 1-93.
[33]	Rummel-Kluge, C., Komossa, K., Schwarz, S., et al. (2010) Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophrenia Research, 123, 225-233.
[34]	Papageorgiou, G. (2011) Country differences in patient characteristics and treatment in schizophrenia: Data from a physician-based survey in Europe. European Psychiatry, 26, 17-28. doi:10.1016/S0924-9338(11)71710-2
[35]	Leitao-Azevedo, C.L., de Abreu, M.G.B., Guimaraes, L.R., et al. (2006) Overweight and obesity in schizophrenic patients taking clozapine compared to the use of other antipsychotics. Revista de Psiquiatria do Rio Grande do Sul, 28, 120-128.
[36]	Hsiao, C.-C., Ree, S.-C., Chang, Y.-L., et al. (2004) Obesity in schizophrenic outpatients receiving antipsychotics in Taiwan. Psychiatry and Clinical Neurosciences, 58, 403-409. doi:10.1111/j.1440-1819.2004.01275.x
[37]	Hung, C.-F. (2005) Diabetes mellitus in patients with schizophrenia in Taiwan. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 28, 523-527. doi:10.1016/j.pnpbp.2005.01.003
[38]	Campbell, T.C. and Chen, J.S. (1994) Chronic degenerative diseases: Perspectives from China. The American Journal of Clinical Nutrition, 56, S1153-S1173.
[39]	Hirota, T., Mara, M., Ohguri, M., et al. (1992) Effect of diet and lifestyle on bone mass in Asian young women. The American Journal of Clinical Nutrition, 55, 1168-1173.
[40]	Chien, I.-C., Hsu, J.H., Lin, C.H., et al. (2009) Prevalence of diabetes in patients with schizophrenia in Taiwan: A population-based National Health Insurance study. Schizophrenia Research, 111, 17-22.
[41]	Ferreira, L. (2010) A case-control study of cardiovascular risk factors and cardiovascular risk among patients with schizophrenia in a country in the low cardiovascular risk regions of Europe. Revista Portuguesa de Cardiologia, 29, 1481-1493.
[42]	de Leon, J. and Diaz, F.J. (2005) A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophrenia Research, 76, 135-157. doi:10.1016/j.schres.2005.02.010
[43]	McClave, A.K., McKnight-Eily, L.R., Davis, S.P. and Dube, S.R. (2010) Smoking characteristics of adults with selected lifetime mental illnesses: results from the 2007 national health interview survey. American Journal of Public Health, 100, 2464-2472. doi:10.2105/AJPH.2009.188136
[44]	Ciara, K. and McCreadis, R. (2000) Cigarette smoking and schizophrenia. Advances in Psychiatric Treatment, 6, 327-331.
[45]	Kuman, V. and Postma, P. (2005) Nicotine use in schizophrenia: The self-medication hypothesis. Neuroscience & Biobehavioral Reviews, 29, 1021-1034. doi:10.1016/j.neubiorev.2005.02.006
[46]	Lavin, M.R., Sinis, S.G. and Mason, S.E. (1996) What is the clinical importance of cigarette smoking in schizophrenia? American Journal on Addictions, 5, 189-208.
[47]	Mobascher, A. and Winterer, G. (2008) The molecular and cellular neurobiology of nicotine abuse in schizophrenia. Pharmacopsychiatry, 41, S51-S59. doi:10.1055/s-2008-1081463
[48]	Scottish Schizophrenia Research Group (2000) Smoking habits and plasma lipid peroxide and vitamin E levels in never-treated first-episode patients with schizophrenia: preliminary report. The British Journal of Psychiatry, 176, 290-293.
[49]	Baker, A., Richmond, R. and Haile, M. (2006) A randomized controlled trial of a smoking cessation intervention among people with a psychiatric disorder. American Journal of Psychiatry, 163, 1934-1942. doi:10.1176/appi.ajp.163.11.1934
[50]	Chaves, L. and Shirakawa, I. (2008) Nicotine use in patients with schizophrenia evaluated by the Fagerstr?m Tolerance Questionnaire: A descriptive analysis from a Brazilian sample. Revista Brasileira de Psiquiatria, 30, 350-352. doi:10.1590/S1516-44462008005000014
[51]	De Leon, J., Dadvard, M., Canuso, C. et al. (1995) Schizophrenia and smoking: an epidemiological survey in a state hospital. American Journal of Psychiatry, 152, 453-455.
[52]	Liao, D.-L., Yang, J.-Y., Lee, S.-M., et al. (2002) Smoking in Chronic Schizophrenic Inpatients in Taiwan. Neuropsychobiology, 45, 172-175. doi:10.1159/000063666
[53]	Herran, A., de Santiago, A., Sandoya, M., et al. (2004) Determinants of smoking behavior in outpatients with schizophrenia. Schizophrenia Bulletin, 41, 373-381.
[54]	Hughes, J.R., Hatsukami, D.K., Mitchell, J.E., et al. (1986) Prevalence of smoking among psychiatric outpatients. American Journal of Psychiatry, 143, 993-997.
[55]	Gu, D., Kelly, T.N., Wu, X. et al. (2009) Mortality attributable to smoking in China. The New England Journal of Medicine, 360, 150-159. doi:10.1056/NEJMsa0802902
[56]	Nakanishi, N, Takatorigi, T. and Suzuki, K. (2005) Cigarette smoking and the risk of metabolic syndrome in middle-aged Japanese male office workers. Industrial Health, 43, 295-301. doi:10.2486/indhealth.43.295
[57]	Oh, S.W., Yoon, Y.S., Lee, E.S. et al. (2005) Association between cigarette smoking and metabolic syndrome. Diabetes Care, 28, 2064-2066. doi:10.2337/diacare.28.8.2064
[58]	Kelly, D.L., McMahon, R.P., Wehring, H.J. et al. (2011) Cigarette smoking and mortality risk in people with schizophrenia. Schizophrenia Bulletin, 37, 832-838. doi:10.1093/schbul/sbp152
[59]	Dalack, G.W., Healy, D.J. and Meador-Woodruff, J.H. (1998) Nicotine dependence in schizophrenia: Clinical phenomena and laboratory findings. American Journal of Psychiatry, 155, 1490-1501.
[60]	Mortensen, P.B. and Juel, K. (1993) Mortality and causes of death in first-admitted schizophrenic patients. The British Journal of Psychiatry, 163, 183-189.
[61]	Folsom, D. (2009) Improving physical health care for subjects with serious mental illness. In: Meyer, J.M. and Nasrallah, H.A., Eds., Medical Illness and Schizophrenia, 2nd Edition, American Psychiatric Publishing, Washington DC, London, 3-15.
[62]	Kuehn, B.M. (2010) Questionable antipsychotic prescribing remains common, despite serious risks. The Journal of the American Medical Association, 303, 1582-1584. doi:10.1001/jama.2010.453
[63]	Morrato, E.H., Druss, B., Hartung, D.M. et al. (2010) Metabolic testing rates in 3 state medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Archives of General Psychiatry, 67, 17-24. doi:10.1001/archgenpsychiatry.2009.179
[64]	Brenner, S. and Cohen, C.I. (2009) Medical health in aging persons with schizophrenia. In: Meyer, J.M., Nasrallah, H.A. (Eds.), Medical Illness and Schizophrenia, 2nd Edition American Psychiatric Publishing, Washington D.C. and London, pp. 377-413 at 391.
[65]	Brown, S., Inskip, H. and Barraclough, B. (2000) Causes of the excess mortality of schizophrenia. British Journal of Psychiatry, 177, 212-217. doi:10.1192/bjp.177.3.212
[66]	Bae, S.-W. and Brekke, J.S. (2002) Characteristics of Korean-Americans with schizophrenia: A cross-ethnic comparison with African-Americans, Latinos, and Euro- Americans. Schizophrenia Bulletin, 28, 703-717. doi:10.1093/oxfordjournals.schbul.a006974
[67]	Goater, N., King, M., Cole, E., et al. (1999) Ethnicity and Outcomes of psychosis. British Journal of Psychiatry, 175, 34-42. doi:10.1192/bjp.175.1.34